Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

What's Inside Our Daily Updates - Daily Biotech Milestones and Clinical Trial Data

|Includes: Acura Pharmaceuticals, Inc. (ACUR), ANIP, CORT, CRIS, EPRS, ITMN, KERX, SLXP, VNDA

Our database of clinical trial results, stock catalysts, and product sales is updated on a daily basis.  If you're too busy to check what's new on our site we also offer daily updates on new milestones, updates to our database and stocks to watch for the day.

Here's an example email sent to clients on May 4, 2010 (chosen at random):

NEW MILESTONES

ACUR: KG and ACUR said they would file an NDA for Acurox in early 2011 (Note: FDA Anesthetic and Life Support Drugs and Drug Safety AdComm voted 19-1 against approval)
BPAX: Expect GVAX clinical hold to be lifted (to partial hold) soon w/ new prostate CA trial at Hopkins anticipated to begin in 4Q10.
CORT: Pivotal Cushings data for Corlux on track for 4Q10.
CRIS: CUDC-101 enrollment is now complete, final trial data is expected at EORTC-NCI-AACR November 2010 (company has seen responses in gastric CA after 4 cycles).
STEM: HuCNS-SC data presented at AANS

DATABASE UPDATES

CLDA (Santen deal), OMER (OMS103HP data), ANX (financing), BSDM (financing), AUXL (Xiaflex, Testim sales), TRGT (expanded AZN deal), CORT (warrant exercise), POZN (Q1 Treximet sales), ISPH (all sales for Q1), VRX, RPTP (Cysteamine NASH data), PPHM

STOCK WATCH

ITMN: PDUFA today
CRXX: Up pre-market
KERX: Continues upward trend w/ heavy volume pre-market
SLXP: Up pre-market
VNDA: Up pre-market on higher than expected Fanapt revenue

RESEARCH - Not disclosed, coming soon

Andrew Nava, LLC provides institutional and retail healthcare investors with buy-side equity research tools which focus on value-driven investing, profitable trading ideas and clinical, commercial, and regulatory catalysts. Our research is supported by consulting with KOL's, industry professionals, company management, and our database of clinical trial data and upcoming company milestones.

As of June 2010, AndrewNava.com covers over 290 publicly-traded biotechnology and pharmaceutical companies, 100's of clinical trials from more than 1000 approved and development-stage drugs, devices and diagnostics, and over 800 company milestones across 17 different catalyst types.



Disclosure: No positions